Curcumin and Exercise in Chronic Kidney Disease

Vasoconstrictor Responsiveness in Contracting Muscle of CKD: Influence of Acute Curcumin Supplementation

Chronic kidney disease (CKD) is associated with a pro-oxidative and pro-inflammatory state, and this is thought to contribute to a decrease in vascular function leading to greater cardiovascular disease (CVD) risk. Curcumin supplementation has been shown to reduce oxidative stress and improve endothelial function at rest in healthy older humans, although the magnitude of this effect remains unknown during exercise in CKD. The primary aim of this proposal is to determine whether exercising blood flow and vasoconstrictor responsiveness are improved as a result of acute oral supplementation with curcumin in patients with CKD. We hypothesize that: 1) acute curcumin supplementation will increase steady state exercise blood flow, and 2) reduce vasoconstriction induced by an acute sympathetic stimulus (cold pressor test) CKD.

Study Overview

• Status: Withdrawn
• Conditions: Chronic Kidney Diseases; Blood Pressure; Hyperemia; Vasoconstriction
• Intervention / Treatment: Drug: Curcumin; Other: Placebo

Detailed Description

Active muscles require an optimal amount of local blood flow to meet the functional and metabolic demand of the exercising muscle. It is well known that maximal aerobic work capacity and exercise tolerance are reduced in CKD, contributing to functional impairment and loss of independence. A multitude of factors may be responsible for this outcome including reduced blood flow to active muscle beds brought on by greater levels of oxidative stress in CKD. Aging and some individuals with disease (coronary artery disease, hypertension, diabetes) exhibit elevated resting sympathetic nerve activity (SNA), leading to greater vasoconstriction and pressor responses during exercise. However, the magnitude of this effect remains unknown in CKD. Importantly, there are a lack of interventions aimed at improving blood flow and reduce sympathetic mediated vasoconstriction in patients with CKD.

Recent evidence in aging humans suggest that curcumin supplementation improves vascular function by reducing oxidative stress. However, it remains unknown whether acute curcumin supplementation can be regarded as an effective therapeutic strategy aimed at modulating exercise vasodilation and sympathetic mediated vasoconstriction in CKD. Understanding the mechanisms that impair vascular function within exercising muscle is important when understanding implications for systemic blood pressure regulation, cardiovascular disease and functional work capacity in CKD. Therefore, identifying a low cost, non-pharmaceutical intervention and its potential impact on improving vascular function in CKD is a priority in preventative cardiovascular disease medicine.

The present proposal aims to examine the effect of sympathetic vasoconstriction on the differential changes in exercising blood flow in response to acute oral supplementation with curcumin in patients with CKD.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Nicholas Kruse, Ph.D.; Phone Number: 4199662797; Email: nicholas-kruse-1@uiowa.edu
• Study Contact Backup: Name: Diana Jala, M.D.; Phone Number: 7204254154; Email: diana-jalal@uiowa.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria for CKD subjects:

Age 45-80 years old CKD stage III and IV (estimated glomerular filtration rate: 15-60 mL/min/1.73m2) BMI <40 kg/m2-1 Able to give informed consent

Exclusion Criteria for CKD subjects will include answering yes to the following questions:

• Active participation in another study?
• Dialysis?
• End stage renal disease or kidney failure?
• Kidney transplant?
• Sever liver disease or transplant?
• Diabetes?
• Angina (i.e., chest discomfort/pain/pressure upon exertion)
• Severe congestive heart failure?
• Pacemaker/defibrillator?
• Heart arrhythmia (i.e. Atrial fibrillation/flutter)?
• Pregnant, breastfeeding, or unwilling to use adequate birth control?
• Active infection or antibiotic therapy?
• Immunosuppressive therapy within the last 3 months?
• History of stroke?
• Have you had a heart attack in the last 3 months?
• Have you taken curcumin in last 3 months?
• Current use of Hormone Replacement Therapy (if female)?
• Current smoker?
• Anemic (Hemoglobin count <9)?

Inclusion Criteria for healthy middle-age and older subjects:

Age 45-80 years old BMI <40 kg/m2 1 Able to give informed consent

Exclusion Criteria for health older subjects will include answering yes to the following questions:

• Chronic kidney disease?
• Hypertension?
• Asthma?
• Heart disease?
• Clinical depression?
• Autonomic disorders?
• Sleep apnea?
• Sever liver disease or transplant?
• Diabetes?
• Heart attack?
• Angina (i.e., chest discomfort/pain/pressure upon exertion)
• Severe systolic or congestive heart failure?
• Heart angioplasty/stent or bypass surgery?
• Heart valve surgery/replacement or valve disease?
• Pacemaker/defibrillator?
• Heart arrhythmia (i.e. Atrial fibrillation/flutter)?
• Pregnant, breastfeeding, or unwilling to use adequate birth control?
• Active infection or antibiotic therapy?
• Immunosuppressive therapy within the last 3 months?
• Have you taken curcumin in last 3 months?
• Current use of Hormone Replacement Therapy (if female)?
• Current smoker?
• Anemic (Hemoglobin count <9)?

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Patients will receive placebo pill identical in appearance and taste to the supplement	Other: Placebo; Oral supplement one time at 2,000 mg
Experimental: Curcumin; Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials	Drug: Curcumin; Oral supplement one time at 2,000 mg; Other Names: Longvida

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
%change forearm vascular condutance (FVC)	Percentage reduction in FVC in response to acute sympathetic stimulus (cold pressor test; CPT)	2 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
forearm blood flow (FBF)	steady state FBF during forearm hand-grip exercise and CPT	2 hours

Collaborators and Investigators

• Sponsor: University of Iowa

Study record dates

Study Major Dates

• Study Start (Anticipated): November 15, 2020
• Primary Completion (Anticipated): November 1, 2021
• Study Completion (Anticipated): November 1, 2021

Study Registration Dates

• First Submitted: October 17, 2019
• First Submitted That Met QC Criteria: October 17, 2019
• First Posted (Actual): October 21, 2019

Study Record Updates

• Last Update Posted (Estimate): February 20, 2023
• Last Update Submitted That Met QC Criteria: February 16, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Exercise; CKD; Vasoconstrictor Responsiveness
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Hyperemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Curcumin
• Other Study ID Numbers: 201907819

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No